{"DataElement":{"publicId":"3835528","version":"1","preferredName":"Study Treatment Medication of Interest Name","preferredDefinition":"Text term for the name of an agent used in a clinical trial study.","longName":"MED_INTEREST_NM","context":"DCI","contextVersion":"1","DataElementConcept":{"publicId":"3835523","version":"1","preferredName":"Study Treatment Medication of Interest","preferredDefinition":"Research conducted with human subjects or on material of human origin in which an investigator directly interacts with human subjects; includes development of new technologies, mechanism of human diseases, therapy, clinical trials, epidemiology, behavior and health services research._An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process._A drug or medicine that treats or prevents or alleviates the symptoms of disease._A state of curiosity or concern about or attention to something","longName":"2747618v1.0:3835521v1.0","context":"DCI","contextVersion":"1","ObjectClass":{"publicId":"2747618","version":"1","preferredName":"Clinical Study Therapeutic Procedure","preferredDefinition":"Research conducted with human subjects or on material of human origin in which an investigator directly interacts with human subjects; includes development of new technologies, study of mechanisms of human diseases, therapy, clinical trials, epidemiologic, behavior, and health services research.:An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","longName":"C15206:C49236","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clinical Study","conceptCode":"C15206","definition":"Research conducted with human subjects or on material of human origin in which an investigator directly interacts with human subjects; includes development of new technologies, study of mechanisms of human diseases, therapy, clinical trials, epidemiologic, behavior, and health services research.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4C96D9C8-06A5-29B0-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-05-06","endDate":null,"createdBy":"UMLLOADER_CAAERS","dateCreated":"2008-05-06","modifiedBy":"ONEDATA","dateModified":"2008-05-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3835521","version":"1","preferredName":"Medication Interest","preferredDefinition":"A drug or medicine that treats or prevents or alleviates the symptoms of disease.                           :A state of curiosity or concern about or attention to something","longName":"C459:C60730","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Medication","conceptCode":"C459","definition":"A drug product that contains one or more active and/or inactive ingredients; it is intended to treat, prevent or alleviate the symptoms of disease. This term does not refer to the individual ingredients that make up the product.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Interest","conceptCode":"C60730","definition":"A state of curiosity or concern about or attention to something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E2D687B0-EC3B-B8A9-E040-BB89AD4356E7","latestVersionIndicator":"Yes","beginDate":"2013-07-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-07-31","modifiedBy":"ONEDATA","dateModified":"2013-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E2D687B0-EC4C-B8A9-E040-BB89AD4356E7","latestVersionIndicator":"Yes","beginDate":"2013-07-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-07-31","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"Created for DCRI Pharmacovigilance study per request by T.Locklear. mc 7/31/13","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3835525","version":"1","preferredName":"Clinical Study Medication Name","preferredDefinition":"Research conducted with human subjects or on material of human origin in which an investigator directly interacts with human subjects; includes development of new technologies, mechanism of human diseases, therapy, clinical trials, epidemiology, behavior and health services research._A drug or medicine that treats or prevents or alleviates the symptoms of disease._The words or language units by which a thing is known.","longName":"3835525v1.0","context":"DCI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Gabapentin","valueDescription":"Gabapentin","ValueMeaning":{"publicId":"2576881","version":"1","preferredName":"Gabapentin","longName":"2576881","preferredDefinition":"A substance that is being studied as a treatment for relieving hot flashes in women with breast cancer.  It belongs to the family of drugs called anticonvulsants.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gabapentin","conceptCode":"C1108","definition":"A synthetic analogue of the neurotransmitter gamma-aminobutyric acid with anticonvulsant activity. Although its exact mechanism of action is unknown, gabapentin appears to inhibit excitatory neuron activity. This agent also exhibits analgesic properties. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F95E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E2D696CA-9327-9226-E040-BB89AD4309FC","beginDate":"2013-07-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-07-31","modifiedBy":"ONEDATA","dateModified":"2013-07-31","deletedIndicator":"No"},{"value":"Pregabalin","valueDescription":"Pregabalin","ValueMeaning":{"publicId":"3835527","version":"1","preferredName":"Pregabalin","longName":"3835527","preferredDefinition":"A 3-isobutyl derivative of gamma-amino butyric acid (GABA) with anti-convulsant, anti-epileptic, anxiolytic, and analgesic activities. Although the exact mechanism of action is unknown, pregabalin selectively binds to alpha2delta (A2D) subunits of presynaptic voltage-dependent calcium channels (VDCCs) located in the central nervous system (CNS). Binding of pregabalin to VDCC A2D subunits prevents calcium influx and the subsequent calcium-dependent release of various neurotransmitters, including glutamate, norepinephrine, serotonin, dopamine, and substance P, from the presynaptic nerve terminals of hyperexcited neurons; synaptic transmission is inhibited and neuronal excitability is diminished. Pregabalin does not bind directly to GABA-A or GABA-B receptors and does not alter GABA uptake or degradation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pregabalin","conceptCode":"C64625","definition":"A 3-isobutyl derivative of gamma-amino butyric acid (GABA) with anti-convulsant, anti-epileptic, anxiolytic, and analgesic activities. Although the exact mechanism of action is unknown, pregabalin selectively binds to alpha2delta (A2D) subunits of presynaptic voltage-dependent calcium channels (VDCCs) located in the central nervous system (CNS). Binding of pregabalin to VDCC A2D subunits prevents calcium influx and the subsequent calcium-dependent release of various neurotransmitters, including glutamate, norepinephrine, serotonin, dopamine, and substance P, from the presynaptic nerve terminals of hyperexcited neurons; synaptic transmission is inhibited and neuronal excitability is diminished. Pregabalin does not bind directly to GABA-A or GABA-B receptors and does not alter GABA uptake or degradation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E2D696CA-9334-9226-E040-BB89AD4309FC","latestVersionIndicator":"Yes","beginDate":"2013-07-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-07-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E2D696CA-934D-9226-E040-BB89AD4309FC","beginDate":"2013-07-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-07-31","modifiedBy":"ONEDATA","dateModified":"2013-07-31","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3835524","version":"1","preferredName":"Clinical Study Medication Name","preferredDefinition":"Research conducted with human subjects or on material of human origin in which an investigator directly interacts with human subjects; includes development of new technologies, mechanism of human diseases, therapy, clinical trials, epidemiology, behavior and health services research. :A drug or medicine that treats or prevents or alleviates the symptoms of disease.                           :The words or language units by which a thing is known.","longName":"C15206:C459:C42614","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clinical Study","conceptCode":"C15206","definition":"Research conducted with human subjects or on material of human origin in which an investigator directly interacts with human subjects; includes development of new technologies, study of mechanisms of human diseases, therapy, clinical trials, epidemiologic, behavior, and health services research.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Medication","conceptCode":"C459","definition":"A drug product that contains one or more active and/or inactive ingredients; it is intended to treat, prevent or alleviate the symptoms of disease. This term does not refer to the individual ingredients that make up the product.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Name","conceptCode":"C42614","definition":"The words or language units by which a thing is known.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E2D696CA-9300-9226-E040-BB89AD4309FC","latestVersionIndicator":"Yes","beginDate":"2013-07-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-07-31","modifiedBy":"ONEDATA","dateModified":"2013-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E2D696CA-9311-9226-E040-BB89AD4309FC","latestVersionIndicator":"Yes","beginDate":"2013-07-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-07-31","modifiedBy":"REEVESD","dateModified":"2014-11-14","changeDescription":"Created for Pharmacovigilance study per request by T.Locklear. mc 7/31/13","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3835419","version":"1","longName":"Pharmacovigilance-Gabapentin/Pregabalin","context":"DCI","ClassificationSchemeItems":[{"publicId":"3835421","version":"1","longName":"Baseline","context":"DCI"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Medication of Interest","type":"Preferred Question Text","description":"Medication of Interest","url":null,"context":"DCI"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E2D696CA-935D-9226-E040-BB89AD4309FC","latestVersionIndicator":"Yes","beginDate":"2013-07-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-07-31","modifiedBy":"REEVESD","dateModified":"2014-11-14","changeDescription":"Created for Pharmacovigilance study per request by T.Locklear. mc 7/31/13","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}